Schizophrenia



Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia


Condition:   Schizophrenia
Interventions:   Drug: Levetiracetam;   Drug: Placebo
Sponsor:   VA Office of Research and Development
Not yet recruiting - verified January 2017


An Extension Study of Safety and Tolerability of SEP-363856 in Adult Subjects With Schizophrenia


Condition:   Schizophrenia
Intervention:   Drug: SEP-363856
Sponsor:   Sunovion
Recruiting - verified April 2017


A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults With Schizophrenia


Condition:   Schizophrenia
Interventions:   Drug: SEP-363856;   Drug: Placebo - Cap
Sponsor:   Sunovion
Recruiting - verified April 2017


The Optimal Treatment for Treatment-resistant Schizophrenia


Condition:   Schizophrenia
Interventions:   Drug: Risperidone with Clozapine;   Drug: Aripiprazole with Clozapine;   Drug: sodium valproate with Clozapine;   Device: modified electroconvulsive therapy(MECT) with Clozapine;   Device: Magnetic seizure therapy(MST) with Clozapine
Sponsor:   Shanghai Mental Health Center
Not yet recruiting - verified October 2016


Brief Grupal Psychoeducation for Schizophrenia


Condition:   Schizophrenia
Interventions:   Other: Brief Group Psychoeducation;   Other: Treatment as Usual
Sponsors:   Salud Mental Integral S.A.S.;   Universidad de Antioquia
Active, not recruiting - verified September 2016


A 6-month Study to Evaluate Sulforaphane add-on Effects in Treatment of Schizophrenia


Condition:   Schizophrenia
Interventions:   Dietary Supplement: sulforaphane;   Other: placebo
Sponsor:   Central South University
Not yet recruiting - verified August 2016


Repetitive Transcranial Magnetic Stimulation for the Treatment of Negative Symptoms in Schizophrenia Patients.


Condition:   Schizophrenia
Intervention:   Device: Repetitive Transcranial Magnetic Stimulation
Sponsor:   Shanghai Mental Health Center
Not yet recruiting - verified June 2016


A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With Schizophrenia


Condition:   Schizophrenia
Interventions:   Drug: ASP4345;   Drug: Matching Placebo
Sponsor:   Astellas Pharma Global Development, Inc.
Recruiting - verified March 2017


Motivation and Executive Control in Schizophrenia


Condition:   Schizophrenia
Intervention:   Other: realization of computerized exercises
Sponsor:   Hôpital le Vinatier
Recruiting - verified January 2017


Aerobic Exercise for Cognition in Schizophrenia


Condition:   Schizophrenia
Interventions:   Behavioral: Aerobic Exercise;   Behavioral: Balance and Stretching
Sponsors:   VA Office of Research and Development;   Emory University
Recruiting - verified March 2017


A Safety, Tolerability, PK and PD Study of Multiple Oral Doses of SKL15508 in Subjects With Stable Schizophrenia


Condition:   Schizophrenia
Interventions:   Drug: SKL15508;   Drug: Placebo
Sponsor:   SK Life Science
Completed - verified August 2015


F17464 in Acute Schizophrenia Trial


Condition:   Schizophrenia
Interventions:   Drug: F17464;   Drug: Placebo
Sponsor:   Pierre Fabre Medicament
Completed - verified January 2016


Factors Influencing Social Functioning of People With Schizophrenia


Condition:   Schizophrenia
Intervention:  
Sponsors:   Second University of Naples;   University of Turin, Italy;   University of Bari;   University of Genova
Completed - verified November 2016


A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia


Condition:   Schizophrenia
Intervention:   Drug: Aripiprazole
Sponsor:   Otsuka Pharmaceutical Co., Ltd.
Completed - verified October 2016


Randomized Controlled Trial of a Gluten Free Diet In Patients With Schizophrenia Who Are Gliadin-Positive


Condition:   Schizophrenia
Interventions:   Other: Gluten Free Flour;   Other: Wheat Flour
Sponsor:   University of Maryland
Completed - verified May 2017


Pediatric Schizophrenia Efficacy and Safety Study


Condition:   Schizophrenia
Interventions:   Drug: Lurasidone 40 mg;   Drug: Lurasidone 80 mg;   Drug: Placebo 40 or 80 mg
Sponsor:   Sunovion
Completed - verified March 2017


A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients


Condition:   Schizophrenia
Interventions:   Drug: AQW051;   Drug: Placebo
Sponsor:   Novartis Pharmaceuticals
Completed - verified March 2017


Insight in Persons Presenting Schizophrenia or Related Troubles During Hospitalization in Psychiatry


Condition:   Schizophrenia
Intervention:   Other: insight variation measure
Sponsor:   Centre Hospitalier Esquirol
Recruiting - verified January 2017


Sensorimotor Gating in Schizophrenia


Condition:   Schizophrenia
Intervention:   Procedure: acoustic startle testing
Sponsor:   Emory University
Active, not recruiting - verified October 2016


A Multicenter Study of NAP (AL-108) in Schizophrenia


Condition:   Schizophrenia
Interventions:   Drug: AL-108;   Drug: AL-108;   Drug: Placebo;   Drug: Placebo
Sponsors:   University of California, Los Angeles;   University of Maryland;   Washington University School of Medicine;   Massachusetts General Hospital;   Nathan Kline Institute for Psychiatric Research;   Columbia University;   Duke University;   Beth Israel Deaconess Medical Center
Completed - verified January 2017


Cognitive Remediation for Schizophrenia


Condition:   Schizophrenia
Intervention:   Behavioral: Computer Assisted Cognitive Remediation (CACR)
Sponsors:   University of Maryland;   National Institute of Mental Health (NIMH);   VISN 5 Mental Illness Research, Education and Clinical Center
Completed - verified April 2017


Glycine vs Placebo for the Schizophrenia Prodrome


Condition:   Schizophrenia Prodrome
Interventions:   Drug: Glycine;   Drug: Placebo
Sponsors:   Yale University;   Glytech, Inc;   National Alliance for Research on Schizophrenia and Depression
Completed - verified November 2016


Effects of RG1068 (Secretin) on Information Processing in Schizophrenia


Condition:   Schizophrenia
Intervention:   Drug: Subcutaneous Secretin
Sponsors:   Indiana University School of Medicine;   Shekhar, Anantha M.D., Ph.D.;   Repligen Corporation
Completed - verified March 2017


A Long Term Study of Clozapine in Patients With Treatment-resistant Schizophrenia


Condition:   Schizophrenia
Intervention:   Drug: Clozapine
Sponsor:   Novartis
Completed - verified March 2017


Clinical Study Of Schizophrenia in Both Men and Women


Condition:   Schizophrenia
Intervention:   Drug: lamotrigine
Sponsor:   GlaxoSmithKline
Completed - verified August 2016

Refine Your Search Advanced Search